0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Mirum HDV Trial Success Adds New Late Stage Growth Option [Yahoo! Finance]

Mirum Pharmaceuticals, Inc. - common stock (MIRM)  More Company Research Source: Yahoo! Finance
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral activity and normalization of ALT levels, a key marker of liver inflammation. The company indicated that these data support advancing brelovitug toward a Phase 3 study in HDV. For Mirum Pharmaceuticals, which focuses on rare and serious liver diseases, the AZURE-1 readout adds a new clinical milestone to its pipeline story. HDV is a difficult-to-treat infection with limited therapeutic options, so the reported antiviral activity of brelovitug and ALT normalization are likely to draw close attention from clinicians and investors who track specialty hepatology drug development. Looking ahead, the main consideration for you as an investor is how the potential progression to Phase 3 might influence Mirum's development priorities, partnering opportunities, and funding needs. The AZUR [Read more]
IMPACT SNAPSHOT EVENT TIME: MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MIRM alerts
from News Quantified
MIRM
NEWS
MIRM
Earnings
MIRM
Analyst Actions
MIRM
SEC Filings
Stockreport

Mirum HDV Trial Success Adds New Late Stage Growth Option [Yahoo! Finance]

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
More Company Research Source: Yahoo! Finance
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral activity and normalization of ALT levels, a key marker of liver inflammation. The company indicated that these data support advancing brelovitug toward a Phase 3 study in HDV. For Mirum Pharmaceuticals, which focuses on rare and serious liver diseases, the AZURE-1 readout adds a new clinical milestone to its pipeline story. HDV is a difficult-to-treat infection with limited therapeutic options, so the reported antiviral activity of brelovitug and ALT normalization are likely to draw close attention from clinicians and investors who track specialty hepatology drug development. Looking ahead, the main consideration for you as an investor is how the potential progression to Phase 3 might influence Mirum's development priorities, partnering opportunities, and funding needs. The AZUR [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS